Prolgolimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Prolgolimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Prolgolimab can convert its Monoclonal antibody profile and PD-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Prolgolimab (query alias: Prolgolimab) |
|---|---|
| Modality / target | Monoclonal antibody; PD-1; PD-1 inhibitors |
| Highest global status | Phase 3 |
| Originator | Biocad Medical, Inc. |
| Active developers | Shanghai Pharmaceuticals Holding Co., Ltd., Biocad CJSC, Sph Biocad Hk Ltd. |
The MCP disease footprint includes Non-Small Cell Lung Cancer, Metastatic melanoma, Unresectable Melanoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05732805 | Phase 3 | Active, not recruiting | 270 | Progression-free survival |
| NCT05783882 | Phase 3 | Active, not recruiting | 114 | Overall response rate |
| NCT06428487 | Phase 2 | Completed | 30 | Pathological complete response (pCR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Final results of the phase III OCTAVA trial: Clinical benefit of low-dose anti–CTLA-4 plus anti–PD-1 combination vs anti–PD-1 monotherapy in unresectable or metastatic melanoma.
Phase 3; n=271; evaluation: Positive. Reported fields: mPFS = 8.3 month ( 4.2 - 14.8); mPFS = 15.4 month ( 8.4 - NA)
463eP - Single-center prospective clinical study on the assessment of the safety and efficiency of the use of PD1 inhibitor prolgolymab in combination with chemotherapy as a neoadjuvant treatment for patients with primary locally advanced squamous cell carcinoma of the esophagus
Phase 1/2; n=10; evaluation: Positive. Reported fields: MPR = 7.0 Pts
Efficacy and safety of first-line prolgolimab and nurulimab versus nivolumab and ipilimumab in advanced or metastatic melanoma: Indirect treatment comparison.
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: OS: HR = 0.58(95% CI, 0.38 - 0.9), P-Value = 0.015; HR = 0.76(95% CI, 0.47 - 1.22), P-Value = 0.252; OS: HR = 0.58(95% CI, 0.38 - 0.9), P-Value = 0.015; HR = 0.76(95% CI, 0.47 - 1.22), P-Value = 0.252; OS: HR = 0.58(95% CI, 0.38 - 0.9), P-Value = 0.015; HR = 0.76(95% CI, 0.47 - 1.22), P-Value = 0.252
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Prolgolimab addresses Non-Small Cell Lung Cancer, Metastatic melanoma, Unresectable Melanoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2019-06-05 | 上海医药集团与BIOCAD HK签署合资协议，设立合资公司SPH-BIOCAD (HK) Limited | Phase 3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Imidazolinone derivative combined with PD-1 or PD-l1 inhibitor for use in the treatment of tumors”. The milestone feed surfaced a patent-application signal described as “Combination therapy involving antibody-drug conjugates against claudin18.2 and PD1/PD-l axis inhibitors for treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Combination therapy with a CEA x CD28 bispecific antibody and blocking Anti-PD-1 antibodies for enhanced in vivo Anti-tumor activity”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
